UA90233C2 - Способ стабилизации противоопухолевых средств на основе водного раствора соединения платины с дезоксирибонуклеиновой кислотой - Google Patents
Способ стабилизации противоопухолевых средств на основе водного раствора соединения платины с дезоксирибонуклеиновой кислотой Download PDFInfo
- Publication number
- UA90233C2 UA90233C2 UAA200906849A UAA200906849A UA90233C2 UA 90233 C2 UA90233 C2 UA 90233C2 UA A200906849 A UAA200906849 A UA A200906849A UA A200906849 A UAA200906849 A UA A200906849A UA 90233 C2 UA90233 C2 UA 90233C2
- Authority
- UA
- Ukraine
- Prior art keywords
- dna
- solution
- stabilization
- aqueous solution
- fluorouracil
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract description 33
- 239000007864 aqueous solution Substances 0.000 title abstract description 13
- 239000002246 antineoplastic agent Substances 0.000 title abstract description 9
- 230000006641 stabilisation Effects 0.000 title abstract description 9
- 238000011105 stabilization Methods 0.000 title abstract description 9
- 150000003058 platinum compounds Chemical class 0.000 title abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 title abstract 3
- 108020004414 DNA Proteins 0.000 title description 14
- 102000053602 DNA Human genes 0.000 title description 4
- 239000000243 solution Substances 0.000 abstract description 32
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract description 24
- 229960002949 fluorouracil Drugs 0.000 abstract description 19
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract description 18
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 abstract description 17
- 239000004202 carbamide Substances 0.000 abstract description 13
- 239000003381 stabilizer Substances 0.000 abstract description 11
- 229940035893 uracil Drugs 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 3
- 229940045985 antineoplastic platinum compound Drugs 0.000 abstract description 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 description 19
- 229940045136 urea Drugs 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 229920002521 macromolecule Polymers 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 7
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- OQUFOZNPBIIJTN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].OC(=O)CC(O)(C(O)=O)CC(O)=O OQUFOZNPBIIJTN-UHFFFAOYSA-N 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 241000350052 Daniellia ogea Species 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- -1 platinum ion Chemical class 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
- 229960001674 tegafur Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QVEDOQSCNLZPJX-UHFFFAOYSA-N 1h-pyrimidine-2,4-dione;hydrochloride Chemical compound Cl.O=C1C=CNC(=O)N1 QVEDOQSCNLZPJX-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001008774 Neria Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Natural products CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Natural products NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000030883 malignant astrocytoma Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000017363 positive regulation of growth Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к медицине, а именно к противоопухолевым средствам, которые могут быть использованы в лечении злокачественных опухолей, и касается способов стабилизации противоопухолевых средств на основе водного раствора соединений платины. В качестве стабилизирующего агента используют смесь основания фторурацила с урацилом и мочевиной, при снижении концентрации протонов в растворе до рН 8,4 - 9,9.
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAA200906849A UA90233C2 (ru) | 2009-06-30 | 2009-06-30 | Способ стабилизации противоопухолевых средств на основе водного раствора соединения платины с дезоксирибонуклеиновой кислотой |
| EA201100618A EA201100618A1 (ru) | 2008-12-22 | 2009-11-23 | Противоопухолевое средство, способ его получения и способ его стабилизации |
| CN2009801477477A CN102227222B (zh) | 2008-12-22 | 2009-11-23 | 抗肿瘤药物,生产该药物的方法和稳定该药物的方法 |
| BRPI0923273-7A2A BRPI0923273A2 (pt) | 2008-12-22 | 2009-11-23 | Agente anitumor e métodos para sua produção e estabilização |
| BG110926A BG66625B1 (bg) | 2008-12-22 | 2009-11-23 | Антитуморно лекарство, метод за получаването му и метод за стабилизирането му |
| PCT/UA2009/000058 WO2010074662A1 (ru) | 2008-12-22 | 2009-11-23 | Противоопухолевое средство, способ его получения и способ его стабилизации |
| TR2011/04008T TR201104008T1 (tr) | 2008-12-22 | 2009-11-23 | Bir antitümör ilacının oluşturulmasına ve stabilizasyonuna ilişkin yöntemler. |
| PL394863A PL219734B1 (pl) | 2008-12-22 | 2009-11-23 | Lek przeciwnowotworowy, sposób jego wytwarzania oraz sposób jego stabilizacji |
| IL213446A IL213446A (en) | 2008-12-22 | 2011-06-09 | Anti-tumor factor, method of producing said factor and method of stabilization |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAA200906849A UA90233C2 (ru) | 2009-06-30 | 2009-06-30 | Способ стабилизации противоопухолевых средств на основе водного раствора соединения платины с дезоксирибонуклеиновой кислотой |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA90233C2 true UA90233C2 (ru) | 2010-04-12 |
Family
ID=50690488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200906849A UA90233C2 (ru) | 2008-12-22 | 2009-06-30 | Способ стабилизации противоопухолевых средств на основе водного раствора соединения платины с дезоксирибонуклеиновой кислотой |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA90233C2 (ru) |
-
2009
- 2009-06-30 UA UAA200906849A patent/UA90233C2/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2603632T3 (es) | Copolímero en bloque que tiene un grupo ácido fenilborónico introducido en el mismo, y usos del mismo | |
| ES2738983T3 (es) | Composición y procedimiento para la administración segura y eficaz de halopiruvato para el tratamiento del cáncer | |
| US20190315673A1 (en) | 5-BROMO-2-(alpha-HYDROXYPENTYL)BENZOIC ACID SODIUM SALTS IN DIFFERENT CRYSTAL FORMS, AND PREPARATION METHOD THEREOF | |
| CN105521491A (zh) | 浓缩蛋白制剂及其用途 | |
| RS65177B1 (sr) | Formulacije bendamustina | |
| US20130296556A1 (en) | Acid Addition Salts, Hydrates and Polymorphs of 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic Acid Ethylamide and Formulations Comprising These Forms | |
| KR20240017813A (ko) | 신경질환 치료용 약학적 조성물 | |
| IL213446A (en) | Anti-tumor factor, method of producing said factor and method of stabilization | |
| WO1994017794A1 (en) | Blends of glycine derivatives and sugars | |
| JP6702938B2 (ja) | アンタゴニストｉｃ ｃｔｌａ−４アプタマー及びその免疫活性増強への応用 | |
| UA90233C2 (ru) | Способ стабилизации противоопухолевых средств на основе водного раствора соединения платины с дезоксирибонуклеиновой кислотой | |
| ES2809460T3 (es) | Nuevo método de producción de lipoplejo para administración local y fármaco antitumoral que utiliza lipoplejo | |
| JP2014502633A (ja) | 抗ウイルス剤 | |
| WO2008007999A1 (en) | Anti-tumoral, antibacterial and antiviral pharmaceutical composition (variants) | |
| Sekhon | Ionic liquids based active pharmaceutical ingredients | |
| US20170145042A1 (en) | Cysteine-modifying substrate analogue inhibitors of ribose 5-phosphate isomerase for parasitic diseases, along with methods of their formation and use | |
| US11021712B1 (en) | MiRNA mimics and uses thereof | |
| JP6549107B2 (ja) | がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ | |
| JP2009539774A (ja) | 薬物の投与方法 | |
| CN107698639A (zh) | 一类吉西他滨磷酸酯的n‑甲酸酯乏氧活化前药及其应用 | |
| WO2026067447A1 (en) | Small Interfering RNAs Targeting ANT2 and Uses Thereof for Disease Treatment | |
| JP2004522775A (ja) | 抗癌薬 | |
| CN104292177B (zh) | 含腈基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途 | |
| CN104341361B (zh) | 一种腈基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 | |
| George et al. | Hyperthermic response of a mouse fibrosarcoma as modified by phenothiazine drugs |